BioXcel Therapeutics Files for Chapter 11, Taps Teva as Stalking-Horse Bidder in Up to $125M Asset Sale
- BioXcel Therapeutics filed for Chapter 11 bankruptcy on August 27, 2026, after running out of cash to service roughly $112M in secured debt, missing an August 21 deadline under its Oaktree credit agreement.
- Teva Pharmaceuticals agreed to serve as stalking-horse bidder in a court-supervised Section 363 auction for substantially all of BioXcel's assets.
- Teva's opening bid: $57.5M cash at closing plus up to $67.5M in milestones, for up to $125M total plus assumed liabilities.
- Key asset: Igalmi (dexmedetomidine sublingual film), already marketed for agitation in schizophrenia/bipolar disorder; an at-home-use version is under FDA review, with a decision expected around November 14, 2026.
- Competing bids are due October 9, 2026, ahead of a possible auction and bankruptcy-court sale hearing.
A $57.5M floor bid for a company with an FDA-approved, already-marketed drug is the real tell here — Oaktree's credit agreement, not Igalmi's commercial prospects, forced this outcome. Whether Teva's up-to-$125M offer looks cheap hinges entirely on that November 14 at-home sNDA decision: clear it, and the milestone structure lets Teva capture most of the upside for a fraction of what a clean acquisition would cost; miss it, and Teva still walks away with a marketed asset at a steep discount either way. For Teva, this reads as opportunistic bolt-on shopping in neuroscience/CNS rather than strategic necessity — cherry-picking distressed assets is cheaper than building pipeline. The bigger lesson: an approved drug is necessary but not sufficient — BioXcel burned through cash on commercial launch faster than Igalmi could generate returns, and Section 363 stalking-horse auctions are becoming the default off-ramp for single-asset biotechs that can't bridge to profitability.
Teva saddles up as stalking horse bidder for bankrupt BioXcel's neuroscience portfolio ↗